InvestSMART

Genetic Signatures Limited (ASX:GSS)

ALERT: Price-sensitive ASX Announcement for GSS
Current share price for GSS : $0.054 -0.086 (-61.43%)+
Announcement
Release
29 Apr 2026 8:22AM
Price at Release
$0.140
Full Release
download
Summary
Genetic Signatures Limited reported $3 million in sales for Q3 FY2026, largely due to seasonal respiratory testing in Australia. The company held a robust cash balance of $25.7 million as of the end of March 2026. Strategic organizational restructuring is anticipated to deliver $5 million in savings annually from FY2027. A significant agreement was signed with Hvidovre Hospital in Denmark, securing a ten-year supply contract for testing equipment and reagents. Operating cash outflows were $3.5 million, and the firm is transitioning its product development to external specialists to maintain agility while preserving its intellectual property. With an estimated 7.3 quarters of funding available, CEO Maria Halasz will brief investors in June to discuss business progress and future focus areas.
Key Points
  • Sales of $3 million during Q3 FY2026 reflecting seasonal respiratory testing rates in Australia.
  • Cash balance of $25.7 million as of 31 March 2026.
  • Organisational restructuring expected to save $5 million annually starting FY2027.
  • Signed a ten-year agreement with Hvidovre Hospital in Denmark for testing equipment and reagents.
  • Net cash outflow from operating activities was $3.5 million for the quarter.
  • Transition to outsourced product development while maintaining core intellectual property.
  • Estimated 7.3 quarters of funding available based on current cash flow.
  • CEO Maria Halasz to hold an investor briefing in June 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.